DENDRIGHT
Dendright is a clinical stage biopharmaceutical company commercializing an immune tolerizing immunotherapy for rheumatoid arthritis. The Company’ s technology targets dendritic cells that present and orchestrate the body’s immune responses to foreign and self-antigens. Dendright’s tolerizing immunotherapy acts to down regulate the immune system rather than to activate it, such that immune responses to given self-antigens are ‘turned off’. By targeting the cause of autoimmune disease rather than treating the symptoms, Dendright offers the potential for long-lasting treatment by working with the body’s own immune system to fight disease.
DENDRIGHT
Social Links:
Industry:
Biopharma Biotechnology Health Care Pharmaceutical
Address:
Brisbane, Queensland, Australia
Country:
Australia
Website Url:
http://www.dendright.com.au
Status:
Active
Similar Organizations
Realm Therapeutics
Realm Tx is a clinical stage biopharmaceutical company passionately committed to leveraging its proprietary immunomodulatory technology
More informations about "Dendright"
Dendright Pty Ltd - ACNC
We take concerns about registered charities seriously. Find out what we can and can't investigate.See details»
Dendright - Crunchbase Company Profile & Funding
Dendright’s tolerizing immunotherapy acts to down regulate the immune system rather than to activate it, such that immune responses to given self-antigens …See details»
Human trials begin for potential world-first rheumatoid …
Nov 14, 2017 Dendright Pty Ltd was established by UniQuest in 2005 to enable Professor Ranjeny Thomas and her team to find a treatment for Rheumatoid …See details»
Clinical Study Protocol
Dendright Pty. Ltd. Registered Office: Level 7, General Purpose South Building Staff House Road The University of Queensland (St Lucia Campus) Brisbane, Queensland, 4072, AUSTRALIA …See details»
Dendright Pty Ltd - ngodetails.com
Dendright Pty Ltd IS ESTABLISED AS ON 04-Jan-2004 AS A charity IN Queensland and ABN NO OF Dendright Pty Ltd IS 71107527131. NA ADDRESS OF Dendright Pty Ltd IS Level 7, …See details»
Dendright - Email Format & Email Checker | NeverBounce
Dendright's core technology patent, which describes the particulate co-delivery of target antigens and NF-kB inhibitors to immune cells, was granted by the United States Patent and Trademark …See details»
Professor Ranjeny Thomas
She has founded two spin-off companies Dendright (2006-2021), and Liperate in 2022. Her research seeks to understand autoimmune disease and restoration of immune tolerance. Through this work, she developed dendritic cell-based …See details»
Trials bring hope for world-first rheumatoid arthritis …
Nov 14, 2017 Professor Thomas, who is also Dendright’s Chief Scientific Officer, said the phase 1b clinical trial was the bridge to bringing scientific data into clinical practice. “The study team will be monitoring and assessing DEN-181 …See details»
Randomized phase I trial of antigen-specific tolerizing ... - PubMed
Oct 24, 2022 BACKGROUNDAntigen-specific regulation of autoimmune disease is a major goal. In seropositive rheumatoid arthritis (RA), T cell help to autoreactive B cells matures the …See details»
DEN-181 - Drug Targets, Indications, Patents - Synapse - Patsnap
A Phase I, randomised, double-blind, placebo-controlled, single centre, multiple-dose ranging study to investigate the safety, tolerability, and pharmacodynamics of subcutaneously …See details»
A Phase I, randomised, double-blind, placebo-controlled
Sponsors Dendright Most Recent Events 19 Oct 2017 Status changed from planning to not yet recruiting. 10 Jan 2017 New trial record 05 Jan 2017 According to a ... If your organization has …See details»
Randomized phase I trial of antigen-specific tolerizing …
IG, MR, SB, and KC were employees of Janssen when the study took place. HR was CEO of Dendright Pty Ltd at the time of the study. The study funders had no role in the conduct of the …See details»
Dendright advances immunotherapy - BioPharmaDispatch
Nov 17, 2017 Dendright, a company spunout of the University of Queensland, has announced it has commenced first-in-human dosing of its product candidate, DEN-181 in a Phase 1b …See details»
DEN-181 (DEN-181) - 药物靶点：VDR_专利_临床_研发
DEN-181: 一种VDR激动剂药物，由Dendright Pty Ltd. (Dendright Pty Ltd.)公司最早进行研发，目前全球最高研发状态为暂停，作用机制: VDR激动剂(维生素D受体激动剂)，治疗领域: 免疫系 …See details»
DEN-181-靶点: NF-κB_适应症: 类风湿关节炎-临床_专利_批准
DEN-181是由Dendright研发的一种小分子药物，是一种NF-κB抑制剂。 目前该药物最高研发阶段为临床一期，用于治疗类风湿关节炎。 DEN-181-靶点: NF-κB_适应症: 类风湿关节炎-临床_专 …See details»
HOME | The Enright Group
The Enright Group (TEG) is home to 2 distinguished companies rooted in three different sectors. True to tradition, each of our brands build on a family legacy while keeping an unwavering …See details»
Dendrite - Funding, Financials, Valuation & Investors - Crunchbase
Jan 1, 2005 Dendrite has raised 2 rounds. Their latest funding was raised on Jan 1, 2005 from a Private Equity round. Dendrite is registered under the ticker NASDAQ:DRTE . Dendrite is …See details»
Fifth Edition of the World Health Organization Classification of …
This manuscript represents a review of lymphoblastic leukemia/lymphoma (acute lymphoblastic leukemia/lymphoblastic lymphoma), acute leukemias of ambiguous lineage, mixed-phenotype …See details»
How to Prevent Short-Circuiting in Next-Gen Lithium Batteries
Mar 18, 2021 The team solved the dendrite problem by adopting a compromise between solid and liquid states. They made a semisolid electrode, in contact with a solid electrolyte material. …See details»
Structure–stability–function relationships of dendritic spines
Dendritic spines, which receive most of the excitatory synaptic input in the cerebral cortex, are heterogeneous with regard to their structure, stability and function. Spines with large heads …See details»